Get started
Author

Akifumi Kuwano

Observed names: A Kuwano, A. Kuwano, AKIFUMI KUWANO
Institution: Aso Iizuka Hospital
ORCID: 0000-0001-9397-8056
Observed ORCID: 0000-0001-9397-8056
OpenAlex ID: A5059278756
Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients
2019 · Koji Imoto, Motoyuki Kohjima, et al. · Canadian Journal of Gastroenterology and Hepatology · 70
PDF
Effects of high fructose intake on liver injury progression in high fat diet induced fatty liver disease in ovariectomized female mice
2018 · Tomoko Ohashi, Masaki Kato, et al. · Food and Chemical Toxicology · 34
PDF
Metabolic Alteration in Hepatocellular Carcinoma: Mechanism of Lipid Accumulation in Well‐Differentiated Hepatocellular Carcinoma
2021 · Hideo Suzuki, Motoyuki Kohjima, et al. · Canadian Journal of Gastroenterology and Hepatology · 27
PDF
Microcirculatory disturbance in acute liver injury
2021 · Akifumi Kuwano, Miho Kurokawa, et al. · Experimental and Therapeutic Medicine · 22
PDF
Tumor‑infiltrating CD8+ T cells as a biomarker for chemotherapy efficacy in unresectable hepatocellular carcinoma
2023 · Akifumi Kuwano, Masayoshi Yada, et al. · Oncology Letters · 21
PDF
Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/β‑catenin signal activation
2022 · Akifumi Kuwano, Masayoshi Yada, et al. · Oncology Letters · 20
PDF
Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice
2023 · Kenta Motomura, Akifumi Kuwano, et al. · Cancers · 16
PDF
Pirfenidone attenuates acetaminophen-induced liver injury via suppressing c-Jun N-terminal kinase phosphorylation
2021 · Shigeki Tashiro, Masatake Tanaka, et al. · Toxicology and Applied Pharmacology · 16
PDF
Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
2024 · AKIFUMI KUWANO, MASAYOSHI YADA, et al. · Cancer Diagnosis & Prognosis · 12
PDF
An Imaging Feature Predicts Efficacy of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
2023 · AKIFUMI KUWANO, MASAYOSHI YADA, et al. · Cancer Diagnosis & Prognosis · 11
PDF
Serum α‐fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct‐acting antiviral treatment
2021 · Akifumi Kuwano, Masayoshi Yada, et al. · Journal of Viral Hepatitis · 11
WNT/β-catenin Signaling and CD8+ Tumor-infiltrating Lymphocytes in Tremelimumab Plus Durvalumab for Advanced Hepatocellular Carcinoma
2024 · AKIFUMI KUWANO, KOSUKE TANAKA, et al. · In Vivo · 10
NRF2–COX2–PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma
2026 · Shuhei Yamamoto, Takahiro Kodama, et al. · Hepatology · 7
Systemic Chemotherapy for Advanced Hepatocellular Carcinoma in Patients With Child-Pugh class B
2024 · AKIFUMI KUWANO, MASAYOSHI YADA, et al. · Cancer Diagnosis & Prognosis · 7
PDF
Recombinant human soluble thrombomodulin ameliorates acetaminophen‑induced liver toxicity in mice
2019 · Akifumi Kuwano, Motoyuki Kohjima, et al. · Experimental and Therapeutic Medicine · 7
PDF
Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib
2022 · Akifumi Kuwano, Masayoshi Yada, et al. · Journal of Viral Hepatitis · 6
Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso‑high intensity in the hepatobiliary phase of Gd‑EOB‑DTPA‑MRI
2021 · Akifumi Kuwano, Kosuke Tanaka, et al. · Molecular and Clinical Oncology · 6
A case of granulocyte colony-stimulating factor-producing intrahepatic sarcomatoid cholangiocarcinoma
2021 · Akifumi Kuwano, Fumiya Narutomi, et al. · Clinical Journal of Gastroenterology · 6
Tumor‐infiltrating CD8+ T‐cell numbers and serum C‐reactive protein levels as a prognostic biomarker in hepatocellular carcinoma patients receiving atezolizumab plus bevacizumab
2025 · Akifumi Kuwano, Masayoshi Yada, et al. · Hepatology Research · 5
PDF
Risk factors for loss to follow‐up after the start of direct‐acting antiviral treatment for hepatitis C virus infection
2022 · Akifumi Kuwano, Masayoshi Yada, et al. · JGH Open · 5
PDF
Similar Efficacy Between Atezolizumab Plus BevacizumabVersusHepatic Arterial Infusion Chemotherapy For Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Cohort Study
2024 · AKIFUMI KUWANO, MASAYOSHI YADA, et al. · In Vivo · 4
PDF
Combined Ultrasound and Computed Tomography Guidance in Radiofrequency Ablation for Hepatocellular Carcinoma Reduces Local Recurrence Rate
2023 · SHIGEHIRO NAGASAWA, AKIFUMI KUWANO, et al. · Cancer Diagnosis & Prognosis · 4
PDF
FIB‑4 index and serum α‑fetoprotein are useful predictors of hepatocellular carcinoma occurrence in hepatitis B patients with nucleos(t)ide analogs therapy
2023 · Akifumi Kuwano, Masayuki Miyazaki, et al. · Experimental and Therapeutic Medicine · 4
PDF
Upregulated expression of hypoxia reactive genes in peripheral blood mononuclear cells from chronic liver disease patients
2021 · Akifumi Kuwano, Masatake Tanaka, et al. · Biochemistry and Biophysics Reports · 4
PDF
Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study
2025 · AKIFUMI KUWANO, MASAYOSHI YADA, et al. · Anticancer Research · 3
Works count: 52
Citation count: 360
H-index: 11
I10-index: 12
Year
Topic
Type